Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1-2 Study of ASTX660 (Tolinapant) in Advanced Solid Tumors and Lymphomas
2024-516679-33-00Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of tolinapant in head and neck squamous cell carcinoma (HNSCC), diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL) and 4 more, sponsored by Taiho Oncology. Primary endpoint: Incidence of SAEs. Started Sep 2024; status: completed.
02
Drugs
tolinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)Cervical Cancer (CC)
Beyond the preview
Go deeper on 2024-516679-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516679-33-00.